Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
Both are FDA-approved weight-loss injectables. In the head-to-head SURMOUNT-5 trial, tirzepatide cut body weight 20.2% vs semaglutide's 13.7% at 72 weeks, so tirzepatide averaged more loss; semaglutide has stronger placebo-controlled cardiovascular-outcomes evidence. Choice is individual — consult a provider.
Tirzepatide and semaglutide are both FDA-approved injectable medications for chronic weight management. In the head-to-head SURMOUNT-5 trial, tirzepatide reduced body weight by 20.2% at 72 weeks versus 13.7% for semaglutide (Aronne et al., N Engl J Med, 2025). Tirzepatide produced greater average loss; semaglutide has longer cardiovascular-outcomes evidence.
Tirzepatide vs semaglutide at a glance
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Drug class | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Weight-loss brand | Zepbound | Wegovy |
| Diabetes brand | Mounjaro | Ozempic |
| Typical max weekly dose | 10–15 mg subcutaneous | 1.7–2.4 mg subcutaneous |
| Approx. half-life | ~5 days | ~7 days |
| Dosing frequency | Once weekly | Once weekly |
| Mean weight loss (head-to-head, 72 wk) | −20.2% | −13.7% |
| Best-documented cardiovascular outcome | Noninferior MACE vs dulaglutide (SURPASS-CVOT) | 20% MACE reduction vs placebo (SELECT) |
| FDA status | Approved (T2D 2022; obesity 2023) | Approved (T2D 2017; obesity 2021) |
| Most common side effects | Nausea, diarrhea, constipation, vomiting | Nausea, diarrhea, constipation, vomiting |
What is the difference between tirzepatide and semaglutide?
The core difference is the number of receptors each molecule activates. Semaglutide is a single-incretin glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor — it was the first-in-class dual GIP/GLP-1 agonist to reach the U.S. market (Mounjaro prescribing information; FDA, 2022).
Both molecules are structurally engineered analogs of native human incretin hormones, with fatty-acid side chains that bind albumin and extend the half-life enough to allow once-weekly subcutaneous dosing. Semaglutide carries a C18 diacid side chain; tirzepatide uses a C20 diacid, contributing to its roughly 5-day half-life versus semaglutide's roughly 7-day half-life (Mounjaro and Wegovy prescribing information; FDA).
In commercial terms, the same molecules appear under different brand names by indication. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, both manufactured by Eli Lilly. Semaglutide is sold as Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as an oral diabetes tablet, all by Novo Nordisk. When people compare "Zepbound vs Wegovy," they are comparing tirzepatide vs semaglutide at their respective weight-management doses.
For broader context on this drug class, see our GLP-1 receptor agonists explained overview.
How does each drug work for weight loss?
How semaglutide works
Semaglutide mimics GLP-1, an incretin hormone the gut releases after eating. By activating GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, it enhances glucose-dependent insulin secretion, slows gastric emptying, and acts on hypothalamic appetite centers to increase satiety and reduce food intake (Wilding et al., N Engl J Med, 2021). The net effect in clinical trials is a sustained reduction in caloric intake and meaningful weight loss when paired with lifestyle changes.
In the pivotal STEP 1 trial of adults with overweight or obesity without diabetes, once-weekly semaglutide 2.4 mg produced a mean body-weight change of −14.9% at week 68 versus −2.4% with placebo, and 86.4% of the semaglutide group achieved at least 5% weight loss (Wilding et al., N Engl J Med, 2021; PMID 33567185).
How tirzepatide works
Tirzepatide adds GIP-receptor activation on top of the GLP-1 mechanism. GIP is a second incretin hormone that also influences insulin secretion and energy metabolism, and dual agonism appears to amplify appetite suppression and metabolic effects beyond GLP-1 alone. Tirzepatide is described pharmacologically as an "imbalanced" dual agonist with greater relative activity at the GIP receptor (Willard et al., JCI Insight, 2020) — though precisely how the GIP component drives additional weight loss in humans is still an active research question.
In the pivotal SURMOUNT-1 trial of adults with obesity without diabetes, tirzepatide produced mean body-weight reductions of −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) at week 72 versus −3.1% with placebo (Jastreboff et al., N Engl J Med, 2022; PMID 35658024).
The most direct interpretation: semaglutide pulls one incretin lever, tirzepatide pulls two, and in head-to-head testing the two-lever approach produced more weight loss on average. See what is tirzepatide and what is semaglutide for deeper single-compound profiles.
Which causes more weight loss, tirzepatide or semaglutide?
On average, tirzepatide produced more weight loss in the only large randomized head-to-head trial to date. This matters: most "tirzepatide vs semaglutide" comparisons rely on cross-trial inference, but SURMOUNT-5 compared the two drugs directly in the same study.
SURMOUNT-5 (the direct comparison). This 72-week phase IIIb trial randomized 751 adults with obesity (and without diabetes) 1:1 to tirzepatide (titrated to 10 mg or 15 mg) or semaglutide (titrated to 1.7 mg or 2.4 mg), each once weekly with behavioral support. Mean body-weight change was −20.2% with tirzepatide versus −13.7% with semaglutide (Aronne et al., N Engl J Med, 2025; PMID 40353578). Tirzepatide also produced a larger waist-circumference reduction (−18.4 cm vs −13.0 cm). The between-drug difference was statistically significant (P<0.001).
Cross-trial context. The direct result is consistent with the separate placebo-controlled pivotal trials: semaglutide's −14.9% in STEP 1 (Wilding et al., 2021) and tirzepatide's up to −20.9% in SURMOUNT-1 (Jastreboff et al., 2022). Note these were different populations and protocols, so the placebo-controlled trials should be read as supporting context, not as a direct comparison.
Two important caveats. First, these are averages — individual response varies widely, and a given person may lose more on semaglutide than the trial average for tirzepatide. Second, "more weight loss on average" is not the same as "the right choice for everyone": tolerability, cost, cardiovascular history, and provider judgment all factor in. Weight-loss medications are tools used under medical supervision, not products to self-select. Consult your healthcare provider before starting any GLP-1 protocol.
How do the side effects of tirzepatide and semaglutide compare?
Both drugs share the same predominant side-effect profile because both act on GLP-1 receptors in the gut: gastrointestinal symptoms — nausea, diarrhea, vomiting, and constipation — are the most common adverse events for each, and most are mild to moderate and concentrated during dose escalation (Aronne et al., N Engl J Med, 2025; Wilding et al., N Engl J Med, 2021).
| Side effect / outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Most common adverse events | GI: nausea, diarrhea, vomiting, constipation | GI: nausea, diarrhea, vomiting, constipation |
| Timing | Mostly during dose escalation | Mostly during dose escalation |
| GI-related discontinuation (SURMOUNT-5) | ~2.7% | ~5.6% |
| Boxed warning | Risk of thyroid C-cell tumors (rodent data) | Risk of thyroid C-cell tumors (rodent data) |
| Notable cautions | Pancreatitis, gallbladder disease, hypoglycemia (with insulin/sulfonylureas) | Pancreatitis, gallbladder disease, hypoglycemia (with insulin/sulfonylureas) |
In SURMOUNT-5, treatment discontinuation due to gastrointestinal adverse events was lower with tirzepatide (~2.7%) than with semaglutide (~5.6%) (Aronne et al., N Engl J Med, 2025) — a counterintuitive finding given tirzepatide's larger effect on weight, and one reason tirzepatide's tolerability is often described as comparable to or better than semaglutide's despite greater potency.
Both medications carry a boxed warning for the risk of thyroid C-cell tumors based on rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (Mounjaro and Wegovy prescribing information; FDA). Both also list warnings for pancreatitis, gallbladder disease, acute kidney injury (often from dehydration secondary to GI losses), and hypoglycemia when combined with insulin or sulfonylureas. Serious adverse events were uncommon and broadly similar in the trials.
Side-effect severity is individual and dose-dependent. For a fuller breakdown, see our GLP-1 side effects guide. Discuss your full medical history and medication list with a licensed healthcare provider before starting either drug, and report severe or persistent symptoms promptly.
Do tirzepatide and semaglutide have cardiovascular benefits?
This is where the evidence picture differs most, and where semaglutide currently holds the longer track record.
Semaglutide — SELECT. In the SELECT cardiovascular outcomes trial of 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 20% versus placebo (hazard ratio 0.80; 95% CI 0.72–0.90) over a mean 39.8 months (Lincoff et al., N Engl J Med, 2023; PMID 37952131). On the strength of SELECT, semaglutide (Wegovy) carries an FDA indication to reduce cardiovascular risk in this population.
Tirzepatide — SURPASS-CVOT. Tirzepatide's dedicated cardiovascular outcomes trial compared it against an active GLP-1 comparator rather than placebo. In SURPASS-CVOT, among 13,165 patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide for three-point MACE (12.2% vs 13.1%; hazard ratio 0.92; 95.3% CI 0.83–1.01; P=0.003 for noninferiority, P=0.09 for superiority) over a median of about four years (Nicholls et al., N Engl J Med, 2025; PMID pending [VERIFY: PMID for NEJMoa2505928]). Because the comparator was an established cardioprotective drug, noninferiority is a meaningful result, but it is a different evidentiary bar than semaglutide's placebo-controlled superiority.
The practical takeaway: as of mid-2026, semaglutide has direct placebo-controlled evidence of cardiovascular event reduction in people without diabetes, while tirzepatide's cardiovascular evidence so far comes from an active-comparator trial in people with diabetes. This distinction can matter for someone with established heart disease and is a conversation to have with a cardiologist or prescribing provider.
When should someone consider tirzepatide vs semaglutide?
The choice is individualized and belongs with a licensed provider. The scenarios below summarize how the published evidence is commonly weighed — they are educational, not recommendations.
| Scenario | Consideration |
|---|---|
| Greatest average weight loss is the priority | Head-to-head data (SURMOUNT-5) favor tirzepatide on mean weight loss |
| Established cardiovascular disease, no diabetes | Semaglutide has direct placebo-controlled MACE-reduction evidence (SELECT) |
| History of poor GI tolerance | SURMOUNT-5 showed lower GI-related discontinuation with tirzepatide, but individual response varies |
| Insurance covers only one agent | Coverage and formulary status often drive the real-world decision |
| Oral (non-injection) preference | Only semaglutide currently has an oral form (Rybelsus, a diabetes product) |
| Longest real-world safety track record | Semaglutide has been FDA-approved longer (2017 for diabetes) |
No table substitutes for a clinical assessment. Personal factors — thyroid history, pancreatitis risk, pregnancy plans, concurrent medications, kidney function, and cost — can override any general pattern. Consult your healthcare provider to determine whether either medication is appropriate for you.
How much do tirzepatide and semaglutide cost in NYC?
List prices for both branded products are high, and out-of-pocket cost depends heavily on insurance, manufacturer savings programs, and pharmacy. As a general 2026 reference, list prices for branded Zepbound (tirzepatide) and Wegovy (semaglutide) have run on the order of roughly $1,000–$1,350 per month before insurance or coupons [VERIFY: current NYC pharmacy list prices for Zepbound and Wegovy, 2026]. Manufacturer self-pay programs and commercial savings cards can substantially lower this for eligible patients, while Medicare and many Medicaid plans have historically limited coverage for weight-loss-only indications.
In the New York City market, branded products are dispensed through standard retail and specialty pharmacies with a valid prescription. Telehealth platforms also prescribe these medications, with cost and legitimacy varying widely — verify that any provider is licensed and that the product is FDA-approved branded medication, not an unverified compounded or "research" product. For sourcing diligence, see our guidance on evaluating GLP-1 sources.
Cost is one of the strongest real-world determinants of which drug a person actually uses, and it changes frequently. Confirm current pricing, coverage, and eligibility directly with your pharmacy, insurer, and prescribing provider.
Are compounded tirzepatide and semaglutide legal in 2026?
Largely no — the regulatory window for mass compounding has closed, and this is one of the most important things to understand before buying. During the 2022–2024 shortages, compounding pharmacies were permitted to prepare copies of these drugs under specific exemptions. That permission has since ended.
The FDA determined the tirzepatide shortage resolved on October 2, 2024, and the semaglutide shortage resolved in early 2025 (FDA declaratory orders and compounding policy statements, 2024–2025). Following resolution, the FDA's enforcement-discretion periods for compounding lapsed on staggered deadlines through the first half of 2025 — earlier for tirzepatide, later for semaglutide — for both 503A state-licensed pharmacies and 503B outsourcing facilities. Federal courts declined to block these determinations after the Outsourcing Facilities Association sued, so the deadlines held [VERIFY: exact 503A and 503B cutoff dates for each drug].
Then, on April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it found no clinical need for outsourcing facilities to compound these drugs from bulk drug substance, and opened a public comment period through June 29, 2026 (FDA press announcement, April 30, 2026). The agency's Pharmacy Compounding Advisory Committee process is the mechanism through which such bulks-list determinations are typically reviewed [VERIFY: scheduled PCAC meeting date in 2026 for these three substances]. The clear trajectory is toward permanently restricting large-scale compounding of all three molecules.
Practical implication: in 2026, legally obtained tirzepatide and semaglutide for weight management generally means FDA-approved branded products (Zepbound, Wegovy, Mounjaro, Ozempic) dispensed by a licensed pharmacy on a valid prescription. Products marketed as compounded, "generic," "research-grade," or "gray-market" GLP-1s carry legal and safety uncertainty — the FDA logged hundreds of adverse-event reports tied to compounded versions, many involving dosing errors. Legal status varies by jurisdiction; consult a lawyer for binding advice, and consult a licensed healthcare provider before obtaining or using any GLP-1 medication.
Can you stack or switch between tirzepatide and semaglutide?
You should not combine them. Tirzepatide and semaglutide both act on the GLP-1 receptor, so taking them together is redundant and stacks overlapping mechanisms and side effects without an evidence-based rationale — there are no clinical trials supporting concurrent use, and doing so would compound GI and other risks. Neither prescribing label supports combination use.
Switching between them under medical supervision is a different matter and is done in clinical practice — for example, when a patient plateaus, cannot tolerate one drug, or faces a coverage change. Switching is not simply swapping milligrams: the two drugs are not dose-equivalent (a "max" semaglutide dose of 2.4 mg is not interchangeable with a 15 mg tirzepatide dose), so a provider typically restarts titration to manage tolerability. Any cross-titration or switch should be planned and monitored by the prescriber.
For how GLP-1 medications fit into broader fat-loss strategies, see our peptides for fat loss overview. Do not start, stop, switch, or combine these medications without consulting your healthcare provider.
Frequently asked questions
Q: Is tirzepatide or semaglutide better for weight loss? A: In SURMOUNT-5, the only large head-to-head randomized trial, tirzepatide produced greater average weight loss than semaglutide — −20.2% versus −13.7% of body weight at 72 weeks (Aronne et al., N Engl J Med, 2025). On average, tirzepatide was more effective for weight reduction. However, "better on average" does not mean better for every individual: tolerability, cardiovascular history, cost, insurance coverage, and other personal factors all matter, and semaglutide has longer placebo-controlled cardiovascular-outcomes evidence. The right choice is one made with a licensed healthcare provider, not selected from a comparison chart.
Q: What is the difference between Zepbound and Wegovy? A: Zepbound is the brand name for tirzepatide approved for chronic weight management; Wegovy is the brand name for semaglutide approved for the same use. The underlying difference is mechanism: Zepbound's tirzepatide is a dual GIP/GLP-1 receptor agonist, while Wegovy's semaglutide is a single GLP-1 receptor agonist. In head-to-head data, tirzepatide (Zepbound) produced more average weight loss, while semaglutide (Wegovy) carries an FDA indication to reduce cardiovascular events in adults with established cardiovascular disease and overweight or obesity, based on the SELECT trial (Lincoff et al., N Engl J Med, 2023). Both require a prescription.
Q: How much weight can you lose on tirzepatide vs semaglutide? A: In clinical trials, average reductions were roughly 15–21% of body weight for tirzepatide depending on dose (Jastreboff et al., N Engl J Med, 2022) and about 15% for semaglutide 2.4 mg (Wilding et al., N Engl J Med, 2021). In the direct SURMOUNT-5 comparison, tirzepatide averaged −20.2% and semaglutide −13.7% at 72 weeks (Aronne et al., N Engl J Med, 2025). These are trial averages with substantial individual variation; results depend on dose, adherence, diet, and physical activity. Discuss realistic expectations with a healthcare provider.
Q: Which has worse side effects, tirzepatide or semaglutide? A: Both share the same dominant side effects — nausea, diarrhea, vomiting, and constipation — driven by their shared GLP-1 activity, and most are mild to moderate and occur during dose escalation (Aronne et al., N Engl J Med, 2025). In SURMOUNT-5, gastrointestinal-related discontinuation was actually lower with tirzepatide (~2.7%) than with semaglutide (~5.6%), suggesting comparable or better tolerability despite tirzepatide's larger effect. Both carry a boxed warning for thyroid C-cell tumor risk (rodent data) and cautions for pancreatitis and gallbladder disease. Individual tolerance varies; consult your healthcare provider.
Q: Can you take tirzepatide and semaglutide together? A: No. Both medications activate the GLP-1 receptor, so taking them together is mechanistically redundant and would stack overlapping gastrointestinal and other side effects with no supporting clinical evidence. Neither drug's prescribing information supports combination use, and there are no trials of concurrent dosing. Switching from one to the other under medical supervision is sometimes done in practice, but the drugs are not dose-equivalent and require careful re-titration. Any decision to switch should be managed by your prescribing provider.
Q: Is compounded tirzepatide or semaglutide still legal in 2026? A: Largely no. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in early 2025, after which the enforcement-discretion periods that had allowed compounding lapsed for both 503A pharmacies and 503B outsourcing facilities. In April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, with public comment open through June 29, 2026 (FDA, 2026). In practice, legally obtained product now means FDA-approved branded medication on a valid prescription. Legal status varies by jurisdiction; consult a lawyer and a licensed provider.
Q: How long do tirzepatide and semaglutide take to work? A: Both are titrated slowly over weeks to months to limit side effects, and appetite changes are often noticed within the first few weeks. Meaningful weight loss accumulates over time: the pivotal trials measured outcomes at 68 weeks (semaglutide) and 72 weeks (tirzepatide), and weight typically continues declining for roughly a year before plateauing (Wilding et al., 2021; Jastreboff et al., 2022). Stopping the medication is associated with weight regain in trial extensions. Timelines and durability should be discussed with a healthcare provider.
References
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. PMID: 40353578 · DOI: 10.1056/NEJMoa2416394
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. PMID: 35658024 · DOI: 10.1056/NEJMoa2206038
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. PMID: 33567185 · DOI: 10.1056/NEJMoa2032183
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232. PMID: 37952131 · DOI: 10.1056/NEJMoa2307563
- Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). N Engl J Med. 2025;393:2409–2420. DOI: 10.1056/NEJMoa2505928 [VERIFY: PMID]
- Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138–150. PMID: 35015037 · DOI: 10.1001/jama.2021.23619
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMC: PMC7526454 · DOI: 10.1172/jci.insight.140532
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA Drug Alerts and Statements, 2025. fda.gov
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA Press Announcement, April 30, 2026. fda.gov
- Eli Lilly and Company. Mounjaro (tirzepatide) injection — Prescribing Information / FDA approval. FDA, 2022. investor.lilly.com
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.